All In Biotech

Drug Trial Radar · NCT00651261

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 717 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

717

Actual

Start

Apr 2008

Primary completion

Jul 2016

Study completion Mar 28, 2022

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); Novartis Pharmaceuticals
First posted
Apr 2, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to find out which is better. This research is being done because it is unknown whether the addition of midostaurin to chemotherapy treatment is better than chemotherapy treatment alone. Midostaurin has been tested in over 400 patients and is being studied in a number of illnesses, including AML, colon cancer, and lung cancer. Midostaurin blocks an enzyme, produced by a gene known as FLT3, that may have a role in the survival and growth of AML cells. Not all leukemia cells will have the abnormal FLT3 gene. This study will focus only on patients with leukemia cells with the abnormal FLT3 gene.

Conditions

  • Leukemia

Interventions

  • cytarabineDrug

    Given IV

  • daunorubicinDrug

    Given IV

  • midostaurinDrug

    Given orally

  • placeboOther

    Given orally

  • dexamethasone acetateDrug

    ocular medication administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Duration of study (Up to 10 years)

Locations

176 sites in 2 countries. Site status is shown where the registry gives one.

  • UAB Comprehensive Cancer Center

    Birmingham, Alabama

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • University of California Davis Cancer Center

    Sacramento, California

  • Aurora Presbyterian Hospital

    Aurora, Colorado

  • Boulder Community Hospital

    Boulder, Colorado

  • Penrose Cancer Center at Penrose Hospital

    Colorado Springs, Colorado

  • St. Anthony Central Hospital

    Denver, Colorado

  • Porter Adventist Hospital

    Denver, Colorado

  • Presbyterian - St. Luke's Medical Center

    Denver, Colorado

  • St. Joseph Hospital

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

  • CCOP - Colorado Cancer Research Program

    Denver, Colorado

  • Swedish Medical Center

    Englewood, Colorado

  • North Colorado Medical Center

    Greeley, Colorado

  • Sky Ridge Medical Center

    Lone Tree, Colorado

  • Hope Cancer Care Center at Longmont United Hospital

    Longmont, Colorado

  • McKee Medical Center

    Loveland, Colorado

  • North Suburban Medical Center

    Thornton, Colorado

  • Exempla Lutheran Medical Center

    Wheat Ridge, Colorado

  • Helen and Harry Gray Cancer Center at Hartford Hospital

    Hartford, Connecticut

  • Tunnell Cancer Center at Beebe Medical Center

    Lewes, Delaware

  • CCOP - Christiana Care Health Services

    Newark, Delaware

  • University of Florida Shands Cancer Center

    Gainesville, Florida

  • Memorial Cancer Institute at Memorial Regional Hospital

    Hollywood, Florida

  • Baptist Cancer Institute - Jacksonville

    Jacksonville, Florida

  • Florida Hospital Cancer Institute at Florida Hospital Orlando

    Orlando, Florida

  • H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

    Tampa, Florida

  • MBCCOP - Medical College of Georgia Cancer Center

    Augusta, Georgia

  • Charles B. Eberhart Cancer Center at DeKalb Medical Center

    Decatur, Georgia

  • Medical Center of Central Georgia

    Macon, Georgia

  • Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler

    Savannah, Georgia

  • Cancer Research Center of Hawaii

    Honolulu, Hawaii

  • Queen's Cancer Institute at Queen's Medical Center

    Honolulu, Hawaii

  • Illinois CancerCare - Bloomington

    Bloomington, Illinois

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University

    Chicago, Illinois

  • University of Illinois Cancer Center

    Chicago, Illinois

  • University of Chicago Cancer Research Center

    Chicago, Illinois

  • Decatur Memorial Hospital Cancer Care Institute

    Decatur, Illinois

  • Cardinal Bernardin Cancer Center at Loyola University Medical Center

    Maywood, Illinois

  • BroMenn Regional Medical Center

    Normal, Illinois

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.